BioCentury
ARTICLE | Company News

Aviragen, HealthCare Royalty Partners deal

May 2, 2016 7:00 AM UTC

Aviragen sold an undisclosed portion of its Inavir laninamivir octanoate royalty rights to HealthCare Royalty Partners for $20 million. Aviragen said it receives about $4.5 million annually from Inav...